高剂量托瑞米芬（每日240毫克）作为晚期乳腺癌的一线激素治疗有效。一项正在进行的芬兰-拉脱维亚多中心II期合作研究。

High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study.

作者信息

Hietanen T, Baltina D, Johansson R, Numminen S, Hakala T, Helle L, Valavaara R

机构信息

Tampere University Central Hospital, Dept. of Radiotherapy, Finland.

出版信息

Breast Cancer Res Treat. 1990 Aug;16 Suppl:S37-40. doi: 10.1007/BF01807143.

DOI:10.1007/BF01807143

PMID:2149284

Abstract

The efficacy of high dose toremifene (240 mg daily) in postmenopausal women with advanced breast cancer is investigated in this ongoing study. At present, 38 patients are fully evaluable. Ten patients have CR (26%), 16 PR (42%) (objective response rate 68%), 8 NC (21%), and 4 PD (11%). Most objective responses are in soft tissue tumors (14/17, 82%). The response rate is equally high in patients with positive or unknown estrogen receptor (ER) status. Median duration of responses and survival are not yet evaluable. Of 48 patients evaluable for side-effects, 22 (46%) experienced some kind of toxicity, which was mild in 64% of cases, moderate in 29%, and mostly of estrogenic type. The study will continue to confirm the results thus far obtained.

摘要

这项正在进行的研究调查了高剂量托瑞米芬（每日240毫克）对绝经后晚期乳腺癌女性的疗效。目前，38例患者可进行全面评估。10例患者达到完全缓解（CR，26%），16例部分缓解（PR，42%）（客观缓解率68%），8例病情稳定（NC，21%），4例疾病进展（PD，11%）。大多数客观缓解出现在软组织肿瘤中（14/17，82%）。雌激素受体（ER）状态为阳性或未知的患者缓解率同样较高。缓解持续时间和生存期的中位数尚未可评估。在48例可评估副作用的患者中，22例（46%）出现了某种毒性反应，其中64%为轻度，29%为中度，且大多为雌激素类型。该研究将继续以确认目前已获得的结果。